Betaxolol: a pilot study of its pharmacological and therapeutic properties in pregnancy.
Twenty two pregnant women with mild to moderate hypertension were treated with betaxolol (10-40 mg/day), a cardioselective beta adrenoceptor blocking agent. The analysis of the changes from the baseline confirmed the antihypertensive effect of the drug with a mean decrease in SBP of 11.8 mm Hg and in DBP of 8.3 mm Hg. A diastolic BP less than 90 mm Hg was obtained in 20 patients after the first day of therapy. Fetal safety, assessed by ultrasonography and cardiotocographic recording was excellent. The 22 mothers gave birth to 23 live born babies (one twin pregnancy). Mean Apgar scores were 8.3 and 9.1 at 1 and 5 min. Only 1 newborn had an Apgar score less than 7. Three newborns suffered from fetal distress and 1 from threat for causes not related to therapy. At 9 months follow-up, all 23 babies were in good health. These data suggest that betaxolol is effective in reducing maternal blood pressure without any deleterious effect on the foetus and the newborn.
Boutroy
M J
MJ
INSERM U-272, Pathologie et biologie du développement humain, Nancy, France.
Morselli
P L
PL
Bianchetti
G
G
Boutroy
J L
JL
Pépin
L
L
Zipfel
A
A
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000097:blood / Q000627:therapeutic use*; D000328:Adult; D015784:Betaxolol / Q000097:blood / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004562:Electrocardiography; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007231:Infant, Newborn; D009929:Organ Size / Q000187:drug effects; D010865:Pilot Projects; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011446:Prospective Studies; D014465:Ultrasonics
D000319:Adrenergic beta-Antagonists; D015784:Betaxolol